Mechanisms of drug resistance in neuroendocrine tumours: A basic research study

#4395

Introduction: Neuroendocrine tumours (NETs) often show resistance to chemotherapy and targeted therapies, leading to treatment failure. However, the molecular mechanisms underlying this resistance remain poorly understood.

Aim(s): To investigate the molecular mechanisms of drug resistance in NETs, focusing on key signalling pathways, genetic mutations, and the tumour microenvironment.

Materials and methods: We used NET cell lines (BON-1, QGP-1) and xenograft mouse models. These models were treated with chemotherapy (cisplatin, etoposide) and targeted therapies (everolimus, sunitinib). We performed genomic analysis to identify mutations and alterations in gene expression. Key signalling pathways (e.g., mTOR, PI3K/AKT) and tumour microenvironment factors were also analysed.

Conference:

Presenting Author:

Authors: Xu L, Yu P, Chen J, Ye M, Xue B,

Keywords: Neuroendocrine tumour, drug resistance, mTOR, PI3K/AKT, tumour microenvironment, chemotherapy,